Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!
Key Clinical PointsCommunity- Acquired PneumoniaThe diagnosis of community - acquired pneumonia is made on the basis of compatible symptoms and signs, with evidence of a new infiltrate on an imaging ...
with novel molecular methods. This has led to different approaches and guidelines for the empiric treatment of community - acquired pneumonia , often with broad-spectrum antimicrobial agents which may play a role ...
recently marketed and more expensive antimicrobials where documentation that these are more effective is not available. Consider, for example, the treatment of community acquired pneumonia in nonhospitalized ...
Purpose of reviewWe highlight the recent advances in the guidelines for treating patients with severe community - acquired pneumonia (sCAP).Recent findingssCAP is a significant cause of hospital ...
of a new syndromic rapid multiplex PCR test (rm-PCR) on respiratory samples to guide empirical antimicrobial therapy in adult patients with community - acquired pneumonia (CAP), hospital- acquired pneumonia ...
with certain risk factors, optimizing therapy for community - acquired pneumonia (CAP) remains a challenge for antimicrobial stewardship (AMS) teams. We investigated the impact of a multimodal AMS initiative ...
greatly complicated the choice of empirical treatment for community - acquired pneumonia (CAP). The newer macrolides, azithromycin and clarithromycin, have been popular choices for empirical therapy because ...
Community - acquired pneumonia (CAP) is a significant cause of morbidity, mortality, and increased cost. Despite numerous managementguidelines, CAP continues to existas a challenge to the learned ...
identified as additional common aetiological agents. Since clinical and roentgenographic features poorly predict the aetiological agent in most cases of community - acquired pneumonia , empirical therapy ...
C NTINUING E DUCATION Optimizing Antiinfective Transition Therapy in Community - Acquired Pneumonia (Pharmacotherapy 2001;21(7 Pt 2):105S–106S) Goal a. Clinical stability b. Clinical deterioration ...
Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!